9 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 14 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 9, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia Iomab-B, Conventional Care, HCT - Acute Myeloid Leukemia, Leukemia, Acute Myeloid | Phase 3 | Active not recruiting | Actinium Pharmaceuticals | 153 | 2016-06-01 | 2023-07-19 |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI) - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Northwell Health | 10 | 2014-12-01 | 2022-04-07 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units. - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Completed | Mesoblast, Ltd. | 49 | 2013-08-01 | 2020-06-26 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 3 | Terminated | Hospital Israelita Albert Einstein | 3 | 2012-12-01 | 2017-03-03 |
| Double Cord Versus Haploidentical (BMT CTN 1101) Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant - Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Medical College of Wisconsin | 368 | 2012-06-01 | 2021-12-01 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) - Myeloid Malignancies, Acute Myelogenous Leukemia | Phase 3 | Terminated | Hackensack Meridian Health | 53 | 2010-06-16 | 2026-04-03 |
| Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Cytarabine plus Daunorubicin [Arm II (AD regimen)] - Acute Myelogenous Leukemia | Phase 3 | Unknown | Cooperative Study Group A for Hematology | 316 | 2010-05-01 | 2010-06-17 |
| A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS Procrit - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 3 | Completed | M.D. Anderson Cancer Center | 51 | 2008-03-01 | 2018-05-30 |
| Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Single Umbilical Cord Blood Unit Transplant, Double Umbilical Cord Blood Unit Transplant, Total Body Irradiation - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 3 | Completed | Medical College of Wisconsin | 224 | 2006-12-01 | 2021-10-28 |
| A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) cytosine arabinoside - Acute Myelogenous Leukemia | Phase 3 | Completed | Northern Italy Leukemia Group | 573 | 2006-11-01 | 2016-03-31 |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) clofarabine (IV formulation), placebo, cytarabine - Acute Myelogenous Leukemia | Phase 3 | Completed | Genzyme, a Sanofi Company | 326 | 2006-08-01 | 2014-04-14 |
| Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) Decitabine - Acute Myelogenous Leukemia | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 50 | 2006-08-01 | 2013-03-04 |
| High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML arm II - ACUTE MYELOGENOUS LEUKEMIA | Phase 3 | Completed | Cooperative Study Group A for Hematology | 398 | 2001-08-01 | 2011-06-10 |
Leukemia, Myeloid, Acute (14) · Myelodysplastic Syndromes (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Hodgkin Disease (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Myeloproliferative Disorders (2) · Burkitt Lymphoma (1) · Graft vs Host Disease (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Leukemia, Myeloid (13) · Leukemia (10) · Bone Marrow Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4)
Cyclophosphamide (4) · Whole-Body Irradiation (4) · Cytarabine (3) · fludarabine (3) · Daunorubicin (2) · fludarabine phosphate (2) · Busulfan (1) · Calcineurin Inhibitors (1) · Clofarabine (1) · Cyclosporine (1) · Decitabine (1) · Dosage Forms (1) · Epoetin Alfa (1) · Idarubicin (1) · Methotrexate (1)
Actinium Pharmaceuticals (2) · Cooperative Study Group A for Hematology (2) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (2) · Genzyme, a Sanofi Company (1) · Hackensack Meridian Health (1) · Hospital Israelita Albert Einstein (1) · Mesoblast, Ltd. (1) · Northern Italy Leukemia Group (1) · Northwell Health (1)
United States (9) · Canada (3) · Italy (2) · South Korea (2) · Australia (1) · Brazil (1) · France (1) · Germany (1)
Mary Horowitz, MD, MS (2) · Avinash Desai, MD (1) · Donna Skerrett, MD, MS (1) · Elizabeth J. Shpall, MD (1) · Farhad Ravandi-Kashani, MD (1) · Je Hwan Lee, Professor (1) · Je Hwan Lee, professor (1) · Joel A Brochstein, MD (1) · Jorge E. Cortes, M.D. (1) · Michele Donato, MD (1) · Paulo V Campregher, MD (1) · Renato Bassan, MD (1)
PMID 21828126, PMID 22585697, PMID 25354103, PMID 30948365, PMID 31978214, PMID 32855275, PMID 33475736, PMID 34273598, PMID 35350938, PMID 37088401, PMID 37120135, PMID 39298738, PMID 39846144, PMID 40227676, PMID 41350757
U24CA076518 (2), 2008 (1), U01HL069294 (1), U10HL069294 (1)